Life Sciences IP Review has partnered with international law firm Gowling WLG to launch the Patent Litigation Survey to appraise the patent trends in biologics, biosimilars and next generation therapies.
A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.
A Novartis unit, Sandoz, has failed to persuade the US Supreme Court to review two Amgen-owned patents on the rheumatoid arthritis drug Enbrel (etanercept).
The World Health Organization has warned the public of the danger of counterfeit COVID-19 vaccines and urged people not to procure jabs outside of government channels.
Massachusetts-based biotechnology start-up Pyxis Oncology has secured a licensing deal with Pfizer for two of the pharmaceutical giant’s antibody-drug conjugates.
Healthcare innovation led patenting activity in 2020 as COVID-19 fuelled a rise in applications, a report by the European Patent Office has revealed.
China must safeguard IP in the seed industry to ensure innovation within the sector, the group chairman of Chinese multinational Sinochem, Frank Ning, has warned.
The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.
On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.
Los Angeles company Puma Biotechnology and Beijing-based CANBridge Pharmaceuticals have cancelled a 2018 licensing deal which gave the latter exclusive rights to a breast cancer drug in China.